Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 9Completed 9Unknown 7Not yet recruiting 3Terminated 2Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Breast Neoplasms 438Neoplasms 322Carcinoma, Non-Small-Cell Lung 250Prostatic Neoplasms 240Lung Neoplasms 176Colorectal Neoplasms 158Pancreatic Neoplasms 148Neoplasm Metastasis 142Leukemia, Myeloid, Acute 140Multiple Myeloma 131Lymphoma 128Carcinoma, Hepatocellular 127Ovarian Neoplasms 109Melanoma 109Head and Neck Neoplasms 101Brain Neoplasms 101Recurrence 100Leukemia 97Leukemia, Lymphocytic, Chronic, B-Cell 96Precursor Cell Lymphoblastic Leukemia-Lymphoma 90Glioblastoma 85Lymphoma, Non-Hodgkin 83Colonic Neoplasms 79Squamous Cell Carcinoma of Head and Neck 76Lymphoma, Follicular 76Carcinoma, Renal Cell 75Lymphoma, Large B-Cell, Diffuse 71Hematologic Neoplasms 69Sarcoma 60Stomach Neoplasms 58

Interventions

1-(4-(4-(3-oxa-8-azabicyclo(3.2.1)octan-8-yl)-6-morpholino-1,3,5-triazin-2-yl)phenyl)-3-(pyridin-4-yl)urea 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Advanced Malignant Solid Tumors × Clear all
NCT00997360 2018-09-27

Study of PKI-179 Administered Orally to Subjects With Solid Tumors

Wyeth is now a wholly owned subsidiary of Pfizer

Phase 1 Withdrawn
Other solid neoplasm

Advanced Malignant Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡